Pharmacoeconomics
theory and practice

- МЕТОДОЛОГИЧЕСКИЕ АСПЕКТЫ ПРОВЕДЕНИЯ ФАРМАКОЭКОНОМИЧЕСКОГО ИССЛЕДОВАНИЯ ТЕРАПИИ СПАСТИЧЕСКИХ ФОРМ ДЕТСКОГО ЦЕРЕБРАЛЬНОГО ПАРАЛИЧА
- МОДЕЛИРОВАНИЕ ВЫЖИВАЕМОСТИ В ФАРМАКОЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЯХ: МОДЕЛЬ МАРКОВА И МОДЕЛЬ РАЗДЕЛЁННОЙ ВЫЖИВАЕМОСТИ
- РЕЗУЛЬТАТЫ РОССИЙСКИХ ФАРМАКОЭКОНОМИЧЕСКИХ ИССЛЕДОВАНИЙ
PHARMAECOENOMIC ANALYSIS OF A MEDICINAL PRODUCT NEOTON (PHOSPHOCREATINE) IN PERIOPERATIVE MANAGEMENT OF CARDIAC SURGERY PATIENTS WITH EXTRACORPOREAL CIRCULATION, WITH ISCHEMIC HEART DISEASE OR WITH CHRONIC HEART INSUFFICIENCY

Kulikov A. Yu.1, Skripnik A.R.2, Bokeria O.L.3, Kudzoeva Z.F.3, Yavorovskiy A.G.1, Eremenko A.A.4

1State Budgetary Educational Institution of Higher Professional Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Heath of the Russian Federation, Moscow
2Financial University under the Government of the Russian Federation
3FSBI A.N. Bakoulev Scientific Center . for Cardiovascular Surgery
4FSBI Russian Scientific Center of Surgery named after academician B.V. Petrovsky

Abstract: Cardiovascular disease (CVD) is the main mortality factor and the main reason of disability of the working-age population both in the Russian Federation and in the world. Due to the state statistical data, 1,878 persons per every 100,000 population died in Russia in 2014. 50.1 % of these deaths have been caused by CVD and more than half of them (52.3 %) have been caused by ischemic heart disease (IHD). The aim of this study was to determine the preferential scheme of medical therapy in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with chronic heart insufficiency (CHI) from the point of view of pharmacoeconomic analysis by comparing ratios between expenses and efficacy, safety and quality of life associated with the use of Neoton (phosphocreatine) in comparison with the control group. Due to the efficacy analysis, the scheme “standard therapy + phosphocreatine” is more effective. Cost-effectiveness analysis has shown that the standard therapy + phosphocreatine is a preferable method of treatment in comparison with the standard therapy as it shows better clinical efficacy and lower “cost-effectiveness ratio. Results of the budget impact analysis have shown that the use of the standard therapy + phosphocreatine instead of the standard therapy itself in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI has saved money.

Key words: efficacy analysis, cost analysis, cost-effectiveness analysis, budget impact analysis, sensitivity analysis, ischemic heart disease, chronic heart insufficiency, pharmacoeconomy, clinico-economic analysis.

Introduction

Rationale of the problem of CVD treatment is doubtless. Due to the data of the World Health Organization (WHO), about 40% of the total number of deaths in 2014 were caused by CVD. Herewith, the half of those deaths were caused by different kinds of IHD.

In Russia, indexes of morbidity and mortality caused by CVD, in particular by IHD, are one of the highest in Europe and in the world. Due to the Federal State Statistics Service, 1,878 persons per every 100,000 population died in Russia in 2014. 50.1 % of these deaths have been caused by CVD and more than half of them (52.3 %) have been caused by IHD [10].

These factors determine the rationale of early diagnostics and appropriate treatment of the pathology. WHO announced that 3/4 of all the deaths caused by CVD, in particular by IHD, may be prevented by early preventive services and remedial actions. It contributes to preservation of more working-age population of the country and to reduction of a disability level.

Introduction of surgical methods of treatment of different heart and vascular diseases with the use of a bypass into clinical practice has significantly reduced the morbidity and mortality levels. The number of cardiac surgeries, including those with the use of the bypass, as well as clinics where they are performed increases each year. For instance, about 50,000 open-heart surgeries were performed in Russia in 2015, whereas the real need is 143,000 surgeries per year [8].

During the last years, development of new surgical technologies, improvement of anesthetic techniques, introduction of monitoring computer systems of estimation and control of vital functions of the body contributed to significant increase of surgeries performed in aged patients and in patients with initially low functional myocardial reserves. It should be mentioned that particular these categories of patients more likely are the subjects of perioperation myocardial ischemia with the development of low cardiac output syndrome. Acute myocardial dysfunction and, as a result, low cardiac output syndrome is one of the worst complications that may develop during cardiac surgeries and reduce to nothing the efficacy of the performed surgery.

One of the reasons of acute myocardial dysfunction is perioperative myocardial infarction (PMI) that is usually accompanied with acute heart insufficiency requiring the use of the expensive treatment.

Due to the literature, over the last years, frequency of PMI constitutes 0.9 - 6.2% depending on the category of operated patients and the experience of coronary artery bypass graft surgeries [1; 2; 5]. Most patients suffer from myocardial infarction during the surgery or within the first days after it. Mortality associated with PMI is approximately 20 - 24%, however, if it is accompanied with the clinics of cardiogenic shock, is constitutes 60-90%.

Modern complex therapy of patients suffering from IHD guarantees a significant clinical response of patients, however, in some cases, the positive effect of such treatment is insufficient.

The use of endovascular and surgical methods, in particular, coronary artery bypass graft surgery (CABG), mammary coronary bypass (MCB), transmyocardial laser revascularization (TMLR), and minimally invasive myocardial revascularization (MIMR) guarantees higher efficacy of the treatment.
Efficacy Analysis

The need for inotropic therapy and chemotherapeutic intervention on the occurrence of the contractile dysfunction of myocardial cardiocytes and in the patients’ life span during extracorporeal circulation, with IHD or with CHI has led to the biggest values of life years gained in comparison with the use of the scheme of standard therapy, in particular 0.96 and 0.88 years for a patient respectively.

Cost Analysis

Cost analysis was the following step of the conducted pharmacoeconomic study. During the study, expenses for the use of the standard therapy + phosphocreatine in comparison with the use of the standard therapy have been determined. Expenses for perioperative and operative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI has been taken into consideration in the study. Final value of the expenses analysis consisted from the direct expenses associated with complications due to the surgery, namely:

1. Cost of medical services and medicinal products for:
   a. therapy of perioperative myocardial infarction;
   b. therapy of arrhythmia in post-operative period;
   c. inotropic therapy;
2. Cost of an inpatient stay:
   a. in cardiac surgical department;
   b. in the resuscitation and intensive care unit.

Time horizon for the study constituted 1 year.

To estimate expenses for medical care, data has been taken from the rate agreement for payment for medical care provided due to compulsory health insurance.
insurance in Moscow city for 2017, and for medical therapy - data on cost of the MP in accordance with the State register of extreme sale prices [9; 11; 12].

For the therapy, phosphocreatine has been introduced into composition of cardioplegic solution immediately prior to bypass 4 g, then for rhythm recovery 4-16 g i.v. by stream infusion depending on the severity of myocard infarct and the intensity of postperiocardiometric violations.

Financial expenses for treatment of perioperative myocardial infarction of cardiac surgery patients comprise of many components including medicinal products, first of all, cardiotonic agents (for instance, MP Levosimendan) and treatment procedures (for instance intra-aortic counterpulsation, stenting of coronary arteries, etc.) and the use of different methods of diagnosing (for instance, echo-cardiography, coronography, catheterization of pulmonary artery, transpulmonary and thermodynamics method of determination of cardiac output, etc.). Yet, this is not a complete list of the used medicines or procedures which should be applied in case of the developed myocardial infarction during surgeries on heart or during the post-operative period. It should be noted that these expenses may increase by several times in case of cardiogenic shock development.

The optimal choice for the products with a positive inotropic effect is a representative of calcium sensitization subgroup - Leveryosimendan (Simdax), with the frequency of administration for improvement of myocardial contractile function - 1 vial as a single dose.

Expenses for a 12-month standard therapy and for a standard therapy + phosphocreatine constituted 83,566 rubles and 75,337 rubles correspondingly (table 2).

Cost-effectiveness

Cost-effectiveness has been conducted at the next stage of the study. Analysis results have been presented as expenses for LYG with the consequent comparison of the received results.

Evaluation of cost-effectiveness ratio (CER) in two groups of patients are specified in the Table 3.

Table 3. Cost-effectiveness analysis in two groups (standard therapy + phosphocreatine vs standard therapy), rubles

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Standard therapy + phosphocreatine</th>
<th>Standard therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expenses</td>
<td>75,337</td>
<td>83,566</td>
</tr>
<tr>
<td>LYG</td>
<td>0.96</td>
<td>0.88</td>
</tr>
<tr>
<td>Coefficient expenses - efficacy (CER)</td>
<td>78,444</td>
<td>95,176</td>
</tr>
</tbody>
</table>

Table 2. Results of the conducted analysis of expenses in the use of standard therapy + phosphocreatine in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI in comparison with the use of standard therapy, rubles

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Rate</th>
<th>Standard therapy + phosphocreatine</th>
<th>Standard therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Frequency</td>
<td>Expenses</td>
</tr>
<tr>
<td>Therapy of perioperative myocardial infarction</td>
<td>288.255</td>
<td>1.40%</td>
<td>4,036</td>
</tr>
<tr>
<td>Therapy of arrhythmia in post-operative period</td>
<td>36,742</td>
<td>11.88%</td>
<td>4,363</td>
</tr>
<tr>
<td>The need of inotropic therapy</td>
<td>24,708</td>
<td>16.75%</td>
<td>4,138</td>
</tr>
<tr>
<td>The need to be nursed in the ICU (on the next day)</td>
<td>8,000</td>
<td>17.00%</td>
<td>9,360</td>
</tr>
<tr>
<td>Inpatient days in the cardiac surgery clinic</td>
<td>5,100</td>
<td>7.3 days</td>
<td>37,230</td>
</tr>
<tr>
<td>Expenses for the product</td>
<td>16,210</td>
<td>100.00%</td>
<td>16,210</td>
</tr>
<tr>
<td>Direct expenses, total</td>
<td>75,337</td>
<td></td>
<td>83,566</td>
</tr>
</tbody>
</table>

1RF Government Regulation as of December 19, 2016 No. 1403 «On State Guarantee Program on Free Universal Health Care for 2017 and for the Planned Period of 2018 and 2019»

2Presented pharmacological aspects of intensive therapy of perioperative myocardial infarction of cardiac surgery patients are based on the experience of treatment of such patients in cardiac surgery clinics of two highly authoritative medical institution of Russia - clinics of cardio-vascular surgery I.M. Sechenov and RSSC named after B.V. Petrovsky

3Data of FSBI A.N. Bakoulev Scientific Center of the MOH of Russia

Due to the results of the conducted cost-effectiveness analysis, in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI in comparison with the use of the standard therapy, it has been determined that due to a positive influence of phosphocreatine on the increase of duration of life, cost-effectiveness ratio for the standard therapy + phosphocreatine has been less and constituted 78,444.

Due to the results of pharmacoeconomic analysis of treatment in perioperative management of cardiac surgery patients of the two groups, it is possible to conclude that the standard therapy + phosphocreatine is a dominant method of treatment in comparison with the standard therapy itself as it demonstrates better clinical efficacy and is characterized by lower cost-effectiveness ratio.

Budget impact analysis

This kind of analysis is an estimation of all the expenses associated with introduction of a new treatment technology or a MP into a real practice taking into consideration its efficacy. Final result is expressed as a sum of money to be saved or spent on the use of estimated medical technology. From the point of view of the budget impact analysis, the dominant position has the technology with lower total expenses.

The results of the budget impact analysis have revealed that the use of the standard therapy + phosphocreatine is preferable as it results in saving 8,229 rubles for a patient in comparison with the standard therapy which corresponds to reduction of expenses by 9.8%.

Sensitivity analysis

Analysis of sensitivity is a compulsory procedure for conduction of pharmacoeconomic study and is used for estimation of stability and efficacy of the conclusions received within the study. A single-factor sensitivity analysis due to the parameter of the cost of the MP Neoton (phosphocreatine) has been used for this study with the aim to determine the stability level of the received pharmacoeconomic conclusions on preference of the MP. Study of the influence of the price change for phosphocreatine in the range of ±50% on pharmacoeconomic study results - cost-effectiveness ratio and the results of the budget impact analysis has been conducted.

The sensitivity results have demonstrated that the change of price for Neoton in the range of 0%–50% to 0%–50%, it is still characterized by lower cost-effectiveness ratio saving money in comparison with the standard therapy (table 4).
results of sensitivity analysis at simultaneous change of price for medicinal products, rubles

<table>
<thead>
<tr>
<th>Change of price for phosphocreatine</th>
<th>Results of the cost-effectiveness analysis</th>
<th>Results of the budget impact analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Standard therapy + phosphocreatine</td>
<td>Standard therapy</td>
</tr>
<tr>
<td>+50%</td>
<td>86,84</td>
<td>95,176</td>
</tr>
<tr>
<td>0</td>
<td>78,444</td>
<td>95,176</td>
</tr>
<tr>
<td>-50%</td>
<td>70,005</td>
<td>95,176</td>
</tr>
</tbody>
</table>

Results

1. Analysis of treatment efficacy in patients has demonstrated the preference of the treatment scheme. In case of the standard therapy + phosphocreatine, the values of life years gained constituted 0.96 years, and in case of the standard therapy – 0.88 years.

2. Due to the results of the conducted analysis of expenses, the cost of a 12-months treatment with standard therapy and with standard therapy + phosphocreatine constituted 83,566 rubles and 75,337 rubles respectively.

3. Cost-effectiveness analysis has shown that the Cost-effectiveness ratio in the group of standard therapy + phosphocreatine constituted 78,444 rubles, whereas in the group of standard therapy - 95,176 rubles. So, standard therapy + phosphocreatine is a dominant method of treatment in comparison with the standard therapy.

4. Due to the results of the budget impact analysis, it has been determined that the use of scheme standard therapy + phosphocreatine resulted in saving of 8,229 rubles per each patient.

5. A single-factor sensitivity analysis due to the parameter of the cost of the MP Neoton has shown the stability of the received results at the change of factor in the range of [-50%; +50%].

Conclusions

Use of phosphocreatine in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI has led to the biggest values of life years gained in comparison with the use of the scheme of standard therapy and is more efficient as: a result of improvement such parameters as: frequency of myocardial infarction cases, frequency of arrhythmia cases, the need in inotropic therapy, the need to stay in DRICU and the number of inpatient days.

Based on the results of pharmacoeconomic analysis of treatment it is possible to conclude: standard therapy + phosphocreatine is a dominant treatment method in comparison with the standard therapy and results in cost saving.

The results of conducted pharmacoeconomic estimation have determined the preference of the standard therapy + phosphocreatine in comparison with the standard therapy in perioperative management of cardiac surgery patients with extracorporeal circulation, with IHD or with CHI from the point of view of the cost-effectiveness analysis parameter: standard therapy - phosphocreatine is characterized by lower cost-effectiveness ratio. From the point of view of budget impact analysis, the standard therapy + phosphocreatine also represents a dominant alternative requiring less expenses and guaranteeing cost saving in the healthcare system in comparison with the standard therapy. So, insignificant increase of the standard therapy cost by adding Neoton makes it possible to prevent perioperative complications and mortality of cardiac surgery patients, is cost saving and makes expenses efficient.

References


12. Rate agreement for payment for medical care provided due to compulsory health insurance in Moscow city for 2017 as of December 29, 2016 [Electronic source] URL: http://mosgorzdrav.ru/ (Date: March 06, 2017)


Table 4. Results of sensitivity analysis at simultaneous change of price for medicinal products, rubles

<table>
<thead>
<tr>
<th>Change of price for phosphocreatine</th>
<th>Results of the cost-effectiveness analysis</th>
<th>Results of the budget impact analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Standard therapy + phosphocreatine</td>
<td>Standard therapy</td>
</tr>
<tr>
<td>+50%</td>
<td>86,84</td>
<td>95,176</td>
</tr>
<tr>
<td>0</td>
<td>78,444</td>
<td>95,176</td>
</tr>
<tr>
<td>-50%</td>
<td>70,005</td>
<td>95,176</td>
</tr>
</tbody>
</table>